Sandoz Names Board Ahead Of Novartis Spinoff
Preparatory Work Begins In June; Formal Constitution Of Board To Follow By Year End
As Sandoz moves closer to being spun off from parent company Novartis, the generics and biosimilars firm has revealed the structure and membership of its board under chair Gilbert Ghostine.
You may also be interested in...
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.
An eventful 2023 for Sandoz saw multiple major deals and key launches, with the year culminating in the firm’s long-awaited spinoff from parent company Novartis in October.
At a pair of capital markets days in New York and London, Sandoz has set out expectations for its post-spinoff future – with biosimilars featuring heavily in the company’s growth plans.